TY - JOUR T1 - Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 JF - Molecular Pharmacology JO - Mol Pharmacol SP - 1193 LP - 1202 DO - 10.1124/mol.107.044610 VL - 74 IS - 5 AU - David J. Nicholls AU - Nick P. Tomkinson AU - Katherine E. Wiley AU - Anne Brammall AU - Lorna Bowers AU - Caroline Grahames AU - Alasdair Gaw AU - Premji Meghani AU - Philip Shelton AU - Tracey J. Wright AU - Philip R. Mallinder Y1 - 2008/11/01 UR - http://molpharm.aspetjournals.org/content/74/5/1193.abstract N2 - The chemokine receptors CXCR1 and CXCR2 are G-protein-coupled receptors (GPCRs) implicated in mediating cellular functions associated with the inflammatory response. Potent CXCR2 receptor antagonists have been discovered, some of which have recently entered clinical development. The aim of this study was to identify key amino acid residue differences between CXCR1 and CXCR2 that influence the relative antagonism by two compounds that have markedly different chemical structures. By investigating the effects of domain switching and point mutations, we found that the second extracellular loop, which contained significant amino acid sequence diversity, was not important for compound antagonism. We were surprised to find that switching the intracellular C-terminal 60 amino acid domains of CXCR1 and CXCR2 caused an apparent reversal of antagonism at these two receptors. Further investigation showed that a single amino acid residue, lysine 320 in CXCR2 and asparagine 311 in CXCR1, plays a predominant role in describing the relative antagonism of the two compounds. Homology modeling studies based on the structure of bovine rhodopsin indicated a potential intracellular antagonist binding pocket involving lysine 320. We conclude that residue 320 in CXCR2 forms part of a potential allosteric binding pocket on the intracellular side of the receptor, a site that is distal to the orthosteric site commonly assumed to be the location of antagonist binding to GPCRs. The existence of a common intracellular allosteric binding site at GPCRs related to CXCR2 may be of value in the design of novel antagonists for therapeutic intervention. The American Society for Pharmacology and Experimental Therapeutics ER -